About
Immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalSan Diego & Southern California
Team (24)
Abraham Bassan
Abraham BassanPrincipal at Samsara BioCapital
A2 Biotherapeutics
team_member
Ada Yeh
Ada YehVice President, Human Resources
A2 Biotherapeutics
executive
Agi Hamburger
Agi Hamburger, Ph.D.Chief Operating Officer
A2 Biotherapeutics
executive
Alexander Kamb
Alexander Kamb, Ph.D.Founder and Chief Scientific Officer
A2 Biotherapeutics
executivefounder
David Maloney
David Maloney, M.D., Ph.D.Fred Hutchinson Cancer Center, Cancer Cell Therapy
A2 Biotherapeutics
team_member
Frederick Locke
Frederick Locke, MDMoffitt Cancer Center, Blood and Marrow Transplant and Cellular Immunotherapy
A2 Biotherapeutics
team_member
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
1,230
By Phase
PHASE1/PHASE2: 3
By Status
RECRUITING: 3ENROLLING_BY_INVITATION: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT06885424Lead Sponsor
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
N/AEnrolling by invitation
400 participants
Started: Aug 31, 2025 · Completed: Mar 31, 2040
NCT06682793Lead Sponsor
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
PHASE1/PHASE2Recruiting
240 participants
Started: May 22, 2025 · Completed: Mar 31, 2030
NCT06051695Lead Sponsor
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
PHASE1/PHASE2Recruiting
230 participants
Started: Apr 3, 2024 · Completed: Jun 30, 2029
NCT05736731Lead Sponsor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
PHASE1/PHASE2Active, not recruiting
160 participants
Started: Apr 28, 2023 · Completed: Dec 31, 2026
NCT04981119Lead Sponsor
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
N/ARecruiting
200 participants
Started: Oct 29, 2021 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Agoura Hills, CA, United States
Map
Loading map...